Compare Consumer Staples Select Sector SPDR Fund (XLP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consumer Staples Select Sector SPDR Fund vs Zoetis Inc — how do they compare? Consumer Staples Select Sector SPDR Fund trades at $85.08, while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| XLP | ZTS | |
|---|---|---|
52-Week High | $90.00 | $156.76 |
52-Week Low | $75.61 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLP trades at $85.08 with minimal daily movement (+0.15%), reflecting stable defensive positioning. Technical indicators show mixed signals with a neutral overall rating, while analyst consensus remains strongly bullish with 100% buy ratings. The consumer staples ETF benefits from recent positive sector momentum and defensive characteristics during market uncertainty.
The outlook remains positive given the defensive nature of consumer staples amid economic uncertainty, with potential for steady dividend income. Key risks include sector rotation away from defensive plays and valuation concerns if growth expectations moderate. The 2.6% dividend yield provides income support while awaiting capital appreciation.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
